CapsoVision entered this earnings day with its stock roughly flat over three months, then slipped 4.9% to close at US$6.46. That pullback sits awkwardly against a company still priced at a rich 23.8x P/S, compared with far lower multiples across the medical equipment peer group.

The headline from this print is not the top line. It is the pressure that elevated valuation now carries on an unprofitable business, even as trailing 12 month revenue reached about US$13.6m. The gap between price and profits is the expectation investors are really trading today.

Love the revenue traction at CapsoVision but concerned about paying a rich P/S for an unprofitable stock? Consider screening for companies that pair steadier balance sheets with more grounded valuations using our list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue (TTM to Q2 2026 vs. TTM to Q2 2025): US$13.56m vs. US$12.04m (revenue grew 12.6%)
• Net Income or Loss (TTM to Q2 2026 vs. TTM to Q2 2025): loss of US$26.97m vs. loss of US$21.07m (loss widened)
• Basic EPS (TTM to Q2 2026 vs. TTM to Q2 2025): loss of US$0.75 per share vs. loss of US$10.09 per share (per share loss narrowed, driven by share count changes and reported EPS)
• Gross Margin (Q2 2026 vs. Q2 2025): 51% vs. 55% (margin contracted)

Prefer clean visuals instead of another wall of earnings tables and P/S ratios? See CapsoVision’s full financial picture, with a clear view of its valuation in our company report for CapsoVision.

CapsoVision growth signals versus earnings pressure

For investors leaning positive on CapsoVision, the latest results offer some support. Revenue for Q2 rose 10% to US$3.6m, with capsule volumes up 13% and the installed base climbing 23%. That lines up with a story of gradually broader clinical use and a stickier ecosystem around CapsoCam and CapsoCloud. Management is leaning into that platform view, highlighting AI Highlights and a growing hospital and GI network footprint. The topline trend backs the idea that the core GI capsule franchise is finding more users, even as the income statement is still far from breakeven.

CapsoVision risks highlighted by widening losses

The cautious view also finds plenty of support. Trailing 12 month revenue grew to about US$13.6m, yet the trailing loss widened to US$26.97m, and operating expenses jumped to US$9.5m in Q2 from US$6.5m. Gross margin slipped to 51% from 55% as pricing pressure and tariffs bit into profitability. Cash sits at US$9.1m with ongoing reliance on external funding, including a US$100m at the market facility. For a company still investing heavily in R&D and clinical programs, these trends keep execution, margin and liquidity risk squarely in focus.

After operating expenses climbed faster than revenue and losses widened, it is fair to ask whether liquidity pressure is just the obvious problem or if investors are missing deeper structural issues behind CapsoVision. Review the full risk analysis for CapsoVision which shows 1 important warning sign

Stay Ahead With Simply Wall St

If CapsoVision’s rich P/S multiple and widening losses have your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that fits your plan. Once you own CapsoVision or any other stock, use the Portfolio Command Center to cut through noise and focus on the most important fundamental and risk alerts. For a longer term view, tap into the Community to see how other investors are thinking about the same opportunities and red flags. That way you spot hidden catalysts and risks earlier and give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond CapsoVision?

Fresh stock ideas can move from quiet to crowded quickly. Use targeted screeners to spot potential breakouts while they are still under the radar and consider acting promptly if they fit your strategy.

• Spot potential momentum stories with real earnings power by reviewing companies in the 76 profitable AI stocks that aren't just burning cash before the crowd catches on and pricing moves ahead of you.
• Hunt for potential defensive compounders by scanning the curated 83 resilient stocks with low risk scores to see which businesses pair steadier risk scores with room for future price momentum.
• Track potential infrastructure tailwinds by checking the focused 38 power grid technology and infrastructure stocks while valuations still reflect early expectations rather than fully priced-in enthusiasm.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.